RSNA 2016

Abstract Archives of the RSNA, 2016


SSM04-01

Body Composition Profiling using MRI - Normative Data for Subjects with Cardiovascular Disease Extracted from the UK Biobank Imaging Cohort

Wednesday, Nov. 30 3:00PM - 3:10PM Room: S504AB



FDA Discussions may include off-label uses.

Olof Dahlqvist Leinhard, PhD, Linkoping, Sweden (Presenter) Stockholder, AMRA AB; Employee, AMRA AB
Jennifer Linge, Linkoping, Sweden (Abstract Co-Author) Employee, AMRA AB
Janne West, MSc, PhD, Linkoping, Sweden (Abstract Co-Author) Employee, AMRA AB; Stockholder, AMRA AB
Jimmy D. Bell, PhD, London, United Kingdom (Abstract Co-Author) Nothing to Disclose
Magnus Borga, PhD, Linkoping, Sweden (Abstract Co-Author) Stockholder, AMRA AB
PURPOSE

To describe the distribution of MRI-derived body composition measurements in subjects with cardiovascular disease (CVD) compared to subjects without any history of CVD.

METHOD AND MATERIALS

1864 males and 2036 females with an age range from 45 to 78 years from the UK Biobank imaging study were included in the study. Visceral adipose tissue volume normalized with height^2 (VATi), total abdominal adipose tissue volume normalized with height^2 (ATATi), total lean thigh muscle volume normalized with body weight (muscle ratio) and liver proton density fat fraction (PDFF) were measured with a 2-point Dixon imaging protocol covering neck to knee and a 10-point Dixon single slice protocol positioned within the liver using a 1.5T MR-scanner (Siemens, Germany). The MR-images were analyzed using AMRA® Profiler research (AMRA, Sweden). 213 subjects with history of cardiovascular events (angina, heart attack, or stroke) (event group) were age and gender matched to subjects with high blood pressure (HBP group), and subjects without CVD (controls).Kruskal-Wallis and Mann-Whitney U tests were used to test the observed differences for each measurement and group without correction for multiple comparisons.

RESULTS

VATi in the event group was 1.73 (1.13 - 2.32) l/m2 (median, 25%-75% percentile) compared to 1.68 (1.19 - 2.23) in the HBP group, and 1.30 (0.82-1.87) in the controls. ATATi in the event group was 4.31 (2.90-5.39) l/m2 compared to 4.05 (3.07-5.12) in the HBP group, and 3.48 (2.48-4.61) in the controls. Muscle ratio in the event group was 0.13 (0.12 - 0.15) l/kg as well as in the HBP group, compared to 0.14 (0.12 - 0.15) in the controls. Liver PDFF in the event group was 2.88 (1.77 - 7.72) % compared to 3.44 (2.04-6.18) in the HBP group, and 2.50 (1.58 - 5.15) in the controls. Kruskal-Wallis test showed significant differences for all variables and group comparisons (p<0.007). The post hoc test showed significant differences comparing the controls to both the event group and the HBP group. These were more significant for VATi and ATATi (p<10-4) than for muscle ratio and PDFF (p<0.03). No significant differences were detected between the event group and the HBP group.

CONCLUSION

Cardiovascular disease is strongly associated with high VATi, liver fat, and ATATi, and with low muscle ratio.

CLINICAL RELEVANCE/APPLICATION

The metabolic syndrome component in CVD can be effectively described using MRI-based body composition profiling.